14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs EPC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Edgewell Personal Care Company (EPC) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas EPC carries 48.4/100 (HOLD) at $28.38 (14.3x Forward P/E, 7.3% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SKIN vs EPC. Trailing 12-month operating profitability (SKIN 2.4% vs EPC 7.3%) and valuation multiples (SKIN 106.4x vs EPC 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Household & Personal Products value chain with $1.3B market capitalization and 7.3% operating margin.
OpEx & R&D Reinvestment35.7% of Rev ($713M)
90D Engineering Disclosures0 Published
Investor FAQ SKIN vs EPC Key Questions & Quantitative Answers
As of Nov 16, 2026, Edgewell Personal Care Company (EPC) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas EPC carries 48.4/100 (HOLD) at $28.38 (14.3x Forward P/E, 7.3% operating margin). Technically, SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure) and EPC sits in a Neutral phase (RSI 50.4, UNCLASSIFIED options structure).
EPC leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with EPC at +3.0% YoY revenue growth and -53.4% YoY earnings growth on $2.00B TTM revenue (43.0% gross margin, 7.3% operating margin). On trailing 12-month operating scale, SKIN generates $289M in USD-normalized revenue versus $2.00B for EPC. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 35.7% of Rev ($713M) (0 disclosures) for EPC.
EPC screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas EPC trades at 14.3x Forward P/E, 13.5x Trailing P/E, 2.87x PEG, and 0.6x EV/Revenue (10.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus EPC (-0.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, EPC carries 40.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 52% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.